Supernus Pharmaceuticals (NASDAQ:SUPN) Upgraded by Zacks Investment Research to “Hold”

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Wednesday, Zacks.com reports.

According to Zacks, “Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. “

Other equities analysts also recently issued reports about the company. StockNews.com upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Monday, April 18th. TheStreet downgraded Supernus Pharmaceuticals from a “b-” rating to a “c+” rating in a research note on Monday, April 18th.

Shares of NASDAQ SUPN traded down $0.35 during trading on Wednesday, hitting $25.48. 12,616 shares of the company were exchanged, compared to its average volume of 452,141. The firm has a market capitalization of $1.36 billion, a PE ratio of 26.00 and a beta of 1.12. Supernus Pharmaceuticals has a 12-month low of $23.15 and a 12-month high of $34.50. The company has a fifty day moving average price of $30.55 and a 200-day moving average price of $30.63. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.63 and a current ratio of 1.91.

Supernus Pharmaceuticals (NASDAQ:SUPNGet Rating) last announced its quarterly earnings data on Monday, May 9th. The specialty pharmaceutical company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.26 by $0.17. The business had revenue of $152.50 million during the quarter, compared to the consensus estimate of $150.47 million. Supernus Pharmaceuticals had a return on equity of 6.75% and a net margin of 9.21%. The business’s revenue for the quarter was up 16.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 earnings per share. Research analysts anticipate that Supernus Pharmaceuticals will post 1.54 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Campbell Newman Asset Management Inc. lifted its stake in shares of Supernus Pharmaceuticals by 2.0% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 22,696 shares of the specialty pharmaceutical company’s stock valued at $734,000 after purchasing an additional 443 shares during the period. Madison Asset Management LLC lifted its stake in Supernus Pharmaceuticals by 0.4% in the 3rd quarter. Madison Asset Management LLC now owns 118,881 shares of the specialty pharmaceutical company’s stock valued at $3,171,000 after purchasing an additional 459 shares during the last quarter. Maryland State Retirement & Pension System lifted its stake in Supernus Pharmaceuticals by 2.2% in the 1st quarter. Maryland State Retirement & Pension System now owns 21,511 shares of the specialty pharmaceutical company’s stock valued at $695,000 after purchasing an additional 460 shares during the last quarter. Retirement Planning Co of New England Inc. lifted its stake in Supernus Pharmaceuticals by 1.3% in the 1st quarter. Retirement Planning Co of New England Inc. now owns 37,969 shares of the specialty pharmaceutical company’s stock valued at $1,227,000 after purchasing an additional 488 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in Supernus Pharmaceuticals by 2.5% during the fourth quarter. DekaBank Deutsche Girozentrale now owns 20,200 shares of the specialty pharmaceutical company’s stock worth $605,000 after acquiring an additional 500 shares during the last quarter.

Supernus Pharmaceuticals Company Profile (Get Rating)

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.

Featured Stories

Get a free copy of the Zacks research report on Supernus Pharmaceuticals (SUPN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.